Patent news - Japan
Ovoca Bio plc is pleased to announce that on 2nd September 2019 its subsidiary, IVIX, received patent No 6552960 in Japan covering pharmaceutical use for a list of peptide variants based on BP-101.
This patent adds to IVIX’s issued patent portfolio consisting of Russian and Israeli patents covering any use for a large list of peptides, and a U.S. patent protecting any pharmaceutical application of peptides in the same list.
IVIX continues to prosecute patent applications in the European Union, Canada, Brazil, India, China and South Korea.
«We are pleased to see the further expansion of our issued patent portfolio with this patent in Japan and its coverage protecting pharmaceutical use of peptides from a list, including our drug candidate BP-101, for the treatment of female sexual dysfunctions, and specifically Hypoactive Sexual Desire Disorder”, said Daniil Nemenov, General director of IVIX. «This further strengthens our position to commercialize BP-101 in markets beyond our initial focus of Russia, where we continue to make strong progress towards obtaining marketing authorization».
For further information:
Ovoca Bio plc
Kirill Golovanov (Chief Executive)
Tel +353 1 661 9819
Davy (Nominated Adviser, Euronext Growth Advisor and Broker)
John Frain / Daragh O'Reilly
Tel: +353 1 679 6363
About Ovoca Bio plc:
Ovoca Bio plc's goal is to become a leader in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. In 2018, Ovoca Bio acquired IVIX and its promising clinical stage asset, BP-101, for female sexual dysfunction, an area of significant unmet medical need. The magnitude of demand for treatments for female sexual dysfunction has only recently been recognized, and Ovoca believes it has the potential to become a substantial pharmaceutical market.
IVIX, a Russian-incorporated company, was formed in 2012 and since that time has sought to develop and subsequently commercialize a proprietary drug candidate, BP-101, for the treatment of female sexual dysfunction. BP-101is a novel synthetic peptide, administered through a nasal spray. Clinical studies completed to-date have demonstrated statistically significant efficacy in the treatment of a major form of female sexual dysfunction. So far, IVIX has reached and completed Phase II and Phase III clinical studies in Russia for BP-101. It now intends to seek approval for the marketing of BP-101in the Russian market, as well seek to expand its use internationally.